340B Matters | Big Pharma Points Fingers at 340B for High Drug Costs
Drugmakers have been driving up prices at an alarming rate, but continue to shift blame for drug costs. This time, its target is the 340B Drug Discount Program.
340B, drug companies
17136
post-template-default,single,single-post,postid-17136,single-format-standard,ajax_fade,page_not_loaded,,qode-title-hidden,qode-theme-ver-9.1.3,wpb-js-composer js-comp-ver-4.11.1,vc_responsive

20 Jun Townhall: Big Pharma Points Fingers While Leaders Fight for Lower Prices

“At a recent hearing of the Senate Finance Committee, Chairman Sen. Chuck Grassley (R-Iowa) warned the seven assembled drug company executives not to point fingers: “It’s time for solutions,” he said.

They didn’t listen. Instead, they blamed everything from pharmacy benefit managers to Medicaid to the popular 340B discount program for why prescription drug prices continue to hit record highs. None of them took any responsibility for their own prices.

It’s an odd logic indeed to accuse the government of distorting a market that it has very little to do with. President Trump and the bipartisan leadership in Congress deserve enormous credit for trying to address the problem of sky-high drug prices, and Big Pharma execs need to stop looking for scapegoats.

Drug makers have been increasing prices at an alarming rate. We all know that medication is a vital part of our healthcare system, but it’s extremely telling that when pressed the pharmaceutical industry could not offer a reasonable explanation for its pricing decisions.”

Read More: https://townhall.com/columnists/maureentestoni/2019/06/19/big-pharma-points-fingers-while-leaders-fight-for-lower-prices-n2548568